RESULTS WITH DACOMITINIB (PF-00299804), AN IRREVERSIBLE PAN-HER TYROSINE KINASE INHIBITOR, IN A PHASE II COHORT OF PATIENTS WITH HER2-MUTANT OR AMPLIFIED LUNG CANCERS

被引：0
|
作者：
Kris, Mark G. [1 ]
Camidge, David Ross [2 ]
Giaccone, Giuseppe [3 ]
Hida, Toyoaki [4 ]
O'Connell, Joseph
Taylor, Ian
Zhang, Hui
Gold-Berg, Zelanna
Jaenne, Pasi A. [5 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Univ Colorado, Boulder, CO 80309 USA
[3] Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC 20057 USA
[4] Aichi Canc Ctr Hosp, Dept Thorac Oncol, Nagoya, Aichi, Japan
[5] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷
关键词：
dacomitinib; tyrosine kinase inhibitor; Lung cancer; phase II;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.11-032
引用
收藏
页码：S609 / S610
页数：2
相关论文
共 50 条
  • [41] Pharmacokinetic assessment of dacomitinib (pan-HER tyrosine kinase inhibitor) in patients with locally advanced head and neck squamous cell carcinoma (LA SCCHN) following administration through a gastrostomy feeding tube (GT)
    Joanne W. Chiu
    Kelvin Chan
    Eric X. Chen
    Lillian L. Siu
    Albiruni R. Abdul Razak
    Investigational New Drugs, 2015, 33 : 895 - 900
  • [42] A PHASE II OPEN LABEL TRIAL OF PF-00299804 MONOTHERAPY IN PATIENTS WITH HER-2 POSITIVE ADVANCED GASTRIC CANCER AFTER FAILURE OF AT LEAST ONE PRIOR CHEMOTHERAPY REGIMEN
    Lee, K. -H.
    Oh, D. -Y.
    Lee, K. -W.
    Cho, J. Y.
    Kang, W. K.
    Rha, S. Y.
    Bang, Y. -J.
    ANNALS OF ONCOLOGY, 2012, 23 : 19 - 20
  • [43] Ado-trastuzumab emtansine in patients with HER2 mutant lung cancers: Results from a phase II basket trial.
    Li, Bob T.
    Shen, Ronglai
    Buonocore, Darren
    Olah, Zachary T.
    Ni, Ai
    Ginsberg, Michelle S.
    Ulaner, Gary
    Weber, Wolfgang
    Ladanyi, Marc
    Won, Helen H.
    Riely, Gregory J.
    Solit, David B.
    Hyman, David Michael
    Rudin, Charles M.
    Berger, Michael F.
    Scaltriti, Maurizio
    Baselga, Jose
    Kris, Mark G.
    Arcila, Maria E.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [44] First-line therapy with dacomitinib, an orally available pan-her tyrosine kinase inhibitor, for locally-advanced or metastatic penile squamous cell carcinoma: Results of an open label, single-arm, single-center, phase 2 study
    Necchi, Andrea
    Lo Vullo, Salvatore
    Raggi, Daniele
    Giannatempo, Patrizia
    Nicolai, Nicola
    Calareso, Giuseppina
    Togliardi, Elena
    Colecchia, Maurizio
    Perrone, Federica
    Gloghini, Annunziata
    Mariani, Luigi
    Salvioni, Roberto
    CANCER RESEARCH, 2017, 77
  • [45] First-line therapy with dacomitinib, an orally available pan-HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open-label, single-arm, single-centre, phase 2 study
    Necchi, Andrea
    Lo Vullo, Salvatore
    Perrone, Federica
    Raggi, Daniele
    Giannatempo, Patrizia
    Calareso, Giuseppina
    Nicolai, Nicola
    Piva, Luigi
    Biasoni, Davide
    Catanzaro, Mario
    Torelli, Tullio
    Stagni, Silvia
    Togliardi, Elena
    Colecchia, Maurizio
    Busico, Adele
    Gloghini, Annunziata
    Testi, Adele
    Mariani, Luigi
    Salvioni, Roberto
    BJU INTERNATIONAL, 2018, 121 (03) : 348 - 356
  • [46] A phase Ⅰ study of Hemay022, an irreversible dual EGFR/HER2 tyrosine kinase inhibitor in Chinese patients with HER2-positive advanced breast cancer
    Pin Zhang
    Lin Wang
    Yueying Zhen
    Zhihong Wang
    Hesheng Zhang
    Richard Jones
    Binghe Xu
    ChineseJournalofCancerResearch, 2024, 36 (01) : 46 - 54
  • [47] A phase II trial of pan-HER inhibitor Poziotinib, in patients with HER2-positive metastatic breast cancer who have received at least two prior HER2-directed regimens: The results of NOV120101-203 trial
    Park, Y. H.
    Lee, K-H.
    Sohn, J.
    Lee, K. S.
    Jung, K. H.
    Kim, J. H.
    Lee, K. H.
    Ahn, J. S.
    Kim, T-Y.
    Kim, G. M.
    Park, I. H.
    Kim, S-B.
    Kim, S. H.
    Han, H. S.
    Im, Y-H.
    Ahn, J. H.
    Kim, J-Y.
    Kang, J.
    Im, S-A.
    ANNALS OF ONCOLOGY, 2017, 28
  • [48] Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor: Results of a Phase II Trial in Patients With Advanced Non-Small-Cell Lung Cancer
    Sequist, Lecia V.
    Besse, Benjamin
    Lynch, Thomas J.
    Miller, Vincent A.
    Wong, Kwok K.
    Gitlitz, Barbara
    Eaton, Keith
    Zacharchuk, Charles
    Freyman, Amy
    Powell, Christine
    Ananthakrishnan, Revathi
    Quinn, Susan
    Soria, Jean-Charles
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18) : 3076 - 3083
  • [49] A phase II trial of the pan-HER inhibitor poziotinib, in patients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial
    Park, Yeon Hee
    Lee, Kyung-Hun
    Sohn, Joo Hyuk
    Lee, Keun Seok
    Jung, Kyung Hae
    Kim, Jee-Hyun
    Lee, Ki Hyeong
    Ahn, Jin Seok
    Kim, Tae-Yong
    Kim, Gun Min
    Park, In Hae
    Kim, Sung-Bae
    Kim, Se Hyun
    Han, Hye Sook
    Im, Young-Hyuck
    Ahn, Jin-Hee
    Kim, Jung-Yong
    Kang, Jahoon
    Im, Seock-Ah
    INTERNATIONAL JOURNAL OF CANCER, 2018, 143 (12) : 3240 - 3247
  • [50] Efficacy and safety of varlitinib, a reversible pan-HER tyrosine kinase inhibitor, in combination with platinum based regimens in biliary tract cancers: A pooled analysis from three phase I studies.
    Tan, Aaron C.
    Oh, Do-Youn
    Chao, Yee
    Hsieh, Chih-Yi
    Chang, Wei-Ling
    Isanto, Fenny
    Chen, Ying-Chen
    McHale, Mark
    Lindmark, Bertil
    Ng, Matthew C. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
12345